Prognosis of prostate cancer with initial prostate-specific antigen > 1,000 ng/mL at diagnosis

Hung Cheng Kan, Chen Pang Hou, Yu Hsiang Lin, Ke Hung Tsui, Phei Lang Chang, Chien Lun Chen

研究成果: 雜誌貢獻文章同行評審

4 引文 斯高帕斯(Scopus)

摘要

Purpose: Prostate cancer patients with surprisingly high prostate-specific antigen (PSA) are encountered clinically. However, descriptions of this group of patients are extremely rare in the published literature. This study reports treatment outcome and long-term prognosis for this group of patients. Patients and methods: Between January 2007 and December 2012, 2,064 patients with PCa diagnosed at a tertiary medical center were retrospectively reviewed. A total of 90 PCa cases were identified with initial PSA (iPSA)>1,000 ng/mL at diagnosis. A retrospective study was conducted in this cohort, with comparison among stratified patient age groups, PSA, treatment options, and overall survival. Results: The mean PSA at PCa diagnosis in this cohort was 3,323 ng/mL (1,003-23,126, median: 2,050 ng/mL). Most patients were in the age group 65-79 years (55/90, 61%). Males older than 80 years had a poor prognosis (P90% of iPSA following primary androgen deprivation therapy (reaching true nadir) could be a predictor of longer survival (P1,000 ng/mL. Reaching a true nadir of PSA following primary androgen deprivation therapy could be a predictor of longer survival. Bilateral orchiectomy is recommended for this group of patients.
原文英語
頁(從 - 到)2943-2949
頁數7
期刊OncoTargets and Therapy
10
DOIs
出版狀態已發佈 - 6月 2017
對外發佈

ASJC Scopus subject areas

  • 腫瘤科
  • 藥學(醫學)

指紋

深入研究「Prognosis of prostate cancer with initial prostate-specific antigen > 1,000 ng/mL at diagnosis」主題。共同形成了獨特的指紋。

引用此